Vicore Pharma Holding AB
NASDAQ:VCREMedical - Pharmaceuticals
-$0.24 today
- Market cap
- $279.65M
- Beta
- 0.15
Volume 0.00M
Average 0.26M
VCRE Operating Cash Flow
Cash generated by the company's core business operations during the period.
Vicore Pharma Holding ABNASDAQ: VCRE
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow declines year over year
Q2 FY2026 operating cash flow of SEK 16.08M (cash outflow) fell 84.9% year over year, behind the -31.6% change in trailing-twelve-month operating cash flow. Sequentially, it fell 86.3% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.
Context
- Operating cash flow amounted to 9843.8% of revenue in FY2025, up 9692.9 pp from a year earlier.
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -84.9% toward the trailing-twelve-month pace of -31.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
SEK · from the cash flow
- Latest · FY2025
- (375.74M) SEK
- Year-over-year change
- -127.8%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (375.74M) | -127.8% |
| FY2024 | 2024-12-31 | (164.95M) | +33.9% |
| FY2023 | 2023-12-31 | (249.58M) | +16.8% |
| FY2022 | 2022-12-31 | (299.92M) | -13.7% |
| FY2021 | 2021-12-31 | (263.82M) | — |
Operating Cash Flow vs competitors
How VCRE compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -31.6% is the lowest of 2, against a peer median of +168.1%.
- Operating cash flow amounts to 16982.6% of revenue for VCRE, versus a peer median of 17.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 225.86M SEK | -31.6% | +7.8% | 16982.6% |
| LTM Jun 2026 | $79.03M USD | +168.1% | +7.7% | 17.5% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding VCRE) | — | +168.1% | +7.7% | 17.5% | |
Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.78M) | (290.73M) | (321.51M) | (194.19M) | (452.39M) |
| Depreciation & Amortization | 397.75K | 3.61M | 3.42M | 2.24M | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | (172.79K) | 0 | 0 | 0 | 0 |
| Change in Working Capital | (37.59K) | (20.94M) | (10.65M) | (1.84M) | 40.81M |
| Accounts Receivables | (37.59K) | (1.6M) | (4.28M) | (35.6M) | (3.08M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 0 | (19.34M) | (6.36M) | 33.77M | 43.89M |
| Other Non-Cash Items | (231.23M) | 8.13M | 79.15M | 28.84M | 35.84M |
| Operating Cash Flow | (263.82M) | (299.92M) | (249.58M) | (164.95M) | (375.74M) |
| Capital Expenditures | 0 | (3M) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (76.61M) | 0 | (199.04M) | (64.81M) | (983.95M) |
| Sales of Investments | 69.64M | 77M | 54.58M | 213.85M | 383.45M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (6.96M) | 74M | (144.46M) | 149.04M | (600.51M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 316.8M | 200M | 500.41M | 882.14M | 455.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (237.78K) | (12.96M) | (29.55M) | (48.08M) | (24.55M) |
| Financing Cash Flow | 316.56M | 187.04M | 470.86M | 834.06M | 430.54M |
| Effect of Forex Changes | (26.64M) | 1.48M | 0 | 4.23M | (32.16M) |
| Net Change in Cash | 2.3M | (37.4M) | 76.82M | 822.38M | (577.85M) |
| Free Cash Flow | (263.82M) | (302.92M) | (249.58M) | (164.95M) | (375.74M) |
Vicore Pharma Holding AB
NASDAQ:VCRE
Intrinsic Alpha fair value
Locked
Current Price
$9.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.